Taipei, Feb 9, 2026 — Golden Biotechnology Corp. (TPEx: 4132, "Golden Biotech") announces the successful completion of its Investigational New Drug (IND) submission to the US FDA for a Phase 3 trial of Antroquinonol (Hocena®) in First-line Metastatic Pancreatic Cancer.

The US FDA has reviewed the submission and issued no Clinical Hold, clearing the path for trial initiation

The Company submitted its Phase III clinical trial application to the FDA on December 31, 2025. The Company plans to proceed with submission to the Institutional Review Board (IRB) and other required regulatory processes in preparation for initiation of the Phase III clinical trial.

The planned Phase III study will evaluate Antroquinonol (Hocena) in combination with standard-of-care chemotherapy (Nab-paclitaxel plus Gemcitabine) as a first-line treatment for patients with metastatic pancreatic cancer. In a previously completed Phase II clinical study, Antroquinonol (Hocena) demonstrated a median overall survival (mOS) of 14.1 months. For reference, the pivotal Phase III study of Nab-paclitaxel plus Gemcitabine reported a median overall survival of 8.5 months.

FORWARD LOOKING STATEMENTS

The statements contained herein may contain certain forward-looking statements relating to Golden Biotechnology Corporation (the “Company”) that are based on the current beliefs and expectations of the Company’s management as well as assumptions made by and information currently available to the Company’s management. These forward-looking statements include, but are not limited to, statements relating to the Company’s business prospects, future developments, trends and conditions in the industry and geographical markets in which the Company operates; the Company’s inventions, patents, patent applications, strategies, plans, objectives and goals; the Company’s ability to control costs; and statements relating to prices, volumes, operations, margins, overall market trends, risk management and exchange rates. These statements can be identified by the use of words such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “seek,” “will,” “expect,”“objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Factors that might cause or contribute to a material difference include, but are not limited to, any changes in the laws, rules and regulations relating to any aspects of the Company’s business operations; governmental or political actions; general industry conditions and competition; general economic factors, including but not limited to interest rate and currency exchange rate fluctuations; the actions and developments of the Company’s competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; the exposure to litigation, including patent litigation, and/or regulatory actions; and factors beyond the Company’s control.

These forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update or reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events. All forward-looking statements herein are qualified by these cautionary statements and there can be no assurance that the actual results or anticipated developments will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company’s business or operations.